Growth Hormone Secretagogues: Sermorelin, Ipamorelin, CJC-1295

Growth hormone secretagogues are the boring middle of the peptide world. They do not produce the dramatic transformations the healing peptides promise (and mostly fail to deliver in humans). They do not have the blockbuster RCT evidence that the GLP-1 class has. They sit in a quieter category where the mechanism is well-understood, the evidence is modest but real, and the effect size in healthy men is smaller than the clinic marketing suggests.

This article is the honest framing of what GH secretagogues actually do, what the evidence says, and how to think about whether a protocol is worth considering. For the broader peptide context, see Peptides: A No-BS Primer and the peptides wiki.

What they are

Growth hormone (GH) is produced by your pituitary gland in pulses throughout the day, with the biggest pulse happening during deep sleep at night. GH declines with age (from roughly age 30 onward), and the decline is one of the factors behind slower recovery, reduced muscle mass, increased body fat, and some of the subtle aging changes in sleep and skin.

Exogenous GH (injected human growth hormone, the same molecule as the natural hormone) can reverse some of these changes but has real downsides: insulin resistance, fluid retention, joint pain, potential cancer risk concerns, and the regulatory and legal complications that come with GH being a controlled substance in many jurisdictions. Exogenous GH is also expensive, typically $1,000-2,500 per month for doses that produce meaningful effects.

GH secretagogues are a different approach. Instead of replacing GH directly, they stimulate your pituitary to release more of its own GH. The advantage is that they preserve your body’s natural pulsatile rhythm, which matters for both efficacy and safety. The disadvantage is that they can only amplify what your pituitary is capable of producing, which is less than exogenous GH doses can deliver.

The three main secretagogues

Three secretagogues make up most of the men’s health optimization conversation: Sermorelin, CJC-1295, and Ipamorelin. They work through two different mechanisms that complement each other.

Sermorelin is a GHRH analog (growth hormone releasing hormone). It mimics the signal your hypothalamus sends to your pituitary to release GH. It has a short half-life (minutes) and stimulates a natural-looking GH pulse. It is the oldest and best-characterized of the three, and it has been in clinical use for decades as a diagnostic agent and occasionally as a treatment. Dose is typically 200-500 mcg subcutaneous, before bed.

CJC-1295 is a longer-acting GHRH analog. The most commonly used version (CJC-1295 without DAC) has a longer half-life than sermorelin but still produces pulsatile release. A separate version (CJC-1295 with DAC) has a much longer half-life and produces more of a sustained elevation in GH, which negates the pulsatility advantage and is less commonly used today. When men talk about CJC-1295 in 2026, they are usually talking about the without-DAC version.

Ipamorelin is a ghrelin mimetic. Ghrelin is the hormone that tells you you are hungry, but it also stimulates GH release through a separate receptor pathway from GHRH. Ipamorelin is a selective ghrelin receptor agonist, meaning it stimulates the GH-releasing part of the ghrelin pathway without the appetite and cortisol effects of older ghrelin agonists. It is almost always combined with CJC-1295 in modern protocols because the two mechanisms are additive.

The standard stack: CJC-1295 (without DAC) plus Ipamorelin, dosed together, subcutaneous injection before bed. Typical dose is 250-500 mcg of each, combined in a single injection. 5 nights per week is the most common frequency. Some men use continuous daily dosing. Some men cycle 12 weeks on, 4 weeks off.

Tesamorelin is worth mentioning as a fourth, more specific secretagogue. It is a GHRH analog FDA-approved for HIV-associated lipodystrophy (visceral fat accumulation in HIV patients on antiretroviral therapy). It has the strongest clinical evidence of any secretagogue for visceral fat reduction, but the approved indication is narrow and off-label use for optimization is less common and more expensive than the CJC-1295/Ipamorelin stack.

What the evidence says

The evidence base for GH secretagogues splits cleanly by population.

In clinical populations (HIV lipodystrophy, pediatric GH deficiency, some adult GH deficiency syndromes), the evidence is solid. Tesamorelin meaningfully reduces visceral fat in HIV patients. Sermorelin produces measurable GH and IGF-1 responses in children with GH deficiency. These populations have clearly defined deficits and the secretagogues address them.

In healthy adults, the evidence is thinner and the effect sizes are smaller. Most of the clinical trials in healthy adults were small, short-duration, and focused on surrogate endpoints like IGF-1 levels or body composition changes over 12-16 weeks. The results are consistent with modest benefit: small improvements in body composition, small improvements in sleep, small improvements in recovery. Nothing dramatic.

The real-world reports from men using the CJC-1295/Ipamorelin stack are split. Some men report meaningful improvements in sleep quality, recovery, and subtle body composition changes. Others report nothing noticeable after 12 weeks. The variance is larger than you would expect from a drug with a predictable effect.

My honest read of the evidence is that GH secretagogues are not a category that produces dramatic outcomes in most healthy men. The men who benefit most are likely those with genuinely suboptimal endogenous GH production, which becomes more common with age but is not universal even in older men. For a 35-year-old with normal GH production, the incremental benefit of a secretagogue stack is likely to be small. For a 55-year-old with declining GH and poor sleep quality, the benefit may be larger and more noticeable.

The sleep connection

One of the most commonly reported benefits of the CJC-1295/Ipamorelin stack is improved sleep quality. This is mechanistically plausible: the GH pulse these peptides stimulate happens during deep sleep, and amplifying that pulse may reinforce the depth and quality of N3 sleep in a feedback loop.

The reason this matters for men’s health is that sleep is the single highest-leverage non-medication variable in the protocol (see Sleep Is the Protocol You’re Ignoring). A secretagogue that improves sleep quality by 10-15% on top of already-good sleep hygiene could be disproportionately valuable, because the downstream effects of better sleep compound into everything else.

The caveat is that the effect is reported more often than it is documented. The controlled trials of secretagogues in healthy adults did not emphasize sleep architecture as a primary endpoint, and the subjective reports of better sleep are vulnerable to placebo effects. The men I have talked to who report real sleep improvements are men who were already paying attention to their sleep and were able to detect a relatively subtle change on top of a good baseline. Men with bad sleep habits who expect a secretagogue to fix their sleep without addressing the foundation are usually disappointed.

The realistic expectations

If you are considering a secretagogue protocol, here is what I would tell you to expect based on the evidence and the anecdote combined.

Possible benefits. Subtle improvement in deep sleep quality. Slightly faster recovery from workouts. Small reduction in visceral fat over 12+ weeks. Slightly improved skin appearance. Small improvement in overall wellbeing in the 2-4 hours after the evening dose.

Unlikely benefits. Dramatic body composition changes. Muscle growth on the order of what you would get from TRT. Energy transformation. Any of the outsized claims some clinic websites make about GH secretagogues.

Side effects. Usually mild. Injection site redness or irritation. Occasional vivid dreams (especially in the first few weeks). Mild water retention in some men. Increased appetite (usually small, especially with ipamorelin-specific ghrelin agonism). Rarely, transient numbness or tingling.

Time to notice anything. Most men who notice benefits notice them in the 4-8 week range. Men who notice nothing by week 12 are unlikely to notice anything by extending the protocol further.

Cost. $150-300 per month through a 503A compounding pharmacy for the CJC-1295/Ipamorelin stack. Tesamorelin is more expensive, typically $500+ per month off-label.

How to think about a protocol

If the realistic expectations above match what you are looking for, and the cost is acceptable, a secretagogue protocol is a reasonable experiment for a man who has already addressed the lifestyle foundation and the TRT question.

The framework I would recommend:

1. Have a clear hypothesis. Are you trying to improve sleep quality? Recovery? Body composition? The protocol is the same but the measurement is different, and knowing what you are testing matters for deciding whether the experiment worked.

2. Have a defined endpoint. 12 weeks is a reasonable first trial. At the end of 12 weeks, you decide whether to continue, adjust, or stop. “I will run this forever because more is better” is the wrong framing.

3. Start with a real 503A pharmacy. The gray market peptide vendors are not the right source. Quality matters. Use a provider and a compounding pharmacy you trust.

4. Keep the protocol simple at first. The standard CJC-1295/Ipamorelin stack, pre-bed, 5 nights a week, for 12 weeks. Do not stack it with other peptides in the first trial. You want to be able to attribute any effects to this protocol, not to a combination that makes the signal ambiguous.

5. Track what you are testing. If it is sleep, use a tracker. If it is recovery, track training metrics. If it is body composition, use DEXA or InBody at the start and end.

6. Be honest about the result. A lot of men want secretagogues to work and will convince themselves they feel better when the data does not support it. Let the data drive the decision about whether to continue.

The access question

The 2023 FDA decision to place CJC-1295, Ipamorelin, and Sermorelin on the Difficult to Compound list temporarily cut off legal 503A access to these peptides. The February 2026 HHS reversal restored access for the 14 peptides affected, including these three. As of this writing, the protocol is legally accessible through PCAB-accredited 503A pharmacies with a valid prescription.

The regulatory direction could shift again. If you are considering a secretagogue protocol, understand that the legal access you have today may not be permanent. For the timeline of the regulatory back-and-forth, see Peptide Access After the Kennedy HHS Announcement and The Compounding Pharmacy Wars.

The honest framing

Growth hormone secretagogues are a real category with a real mechanism and modest but documented effects. They are not a dramatic intervention. They are a small-to-medium lever that may or may not produce benefits you can detect, depending on your starting point and your sensitivity to subtle changes.

For men who have done the foundation work, are on a reasonable TRT protocol if indicated, and are looking for an additional small lever, a secretagogue trial is defensible. For men who are hoping that a peptide will substitute for the boring things that matter, a secretagogue trial will disappoint.

The marketing from some clinics oversells this category. The reality is more modest and more honest. If you go into a secretagogue protocol with calibrated expectations, it is a reasonable experiment. If you go in expecting the internet hype, you will be let down.